Document Detail


Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.
MedLine Citation:
PMID:  17560866     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
After acute coronary syndromes, the beneficial effect of aspirin plus clopidogrel (A+C) or aspirin plus dose-adjusted warfarin (A+W) compared with aspirin alone is well established. However, these regimens were never compared. To compare the risk-benefit profile of A+C versus A+W after acute coronary syndromes, major medical databases for randomized controlled trials comparing 1 of these combined approaches versus aspirin alone after an acute coronary syndrome (updated June 2006) were searched. Evaluated end points were major adverse events [MAEs: all-cause death, acute myocardial infarction [AMI], thromboembolic stroke, major bleeds, and overall risk of stroke [hemorrhagic or ischemic]). Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for (1) A+W versus aspirin alone, (2) A+C versus aspirin alone, and (3) A+W versus A+C using adjusted indirect meta-analysis. Thirteen studies were included, totaling 69,741 patients. Ten compared A+W versus aspirin alone and 3 compared A+C versus aspirin alone. Each combined approach yielded a significantly lower risk of MAEs, albeit an increased risk of major bleeds, compared with aspirin alone. No significant difference was found for A+W versus A+C for risk of overall MAEs, death, or AMI. However, A+W versus A+C was associated with a significantly lower risk of thromboembolic stroke (OR 0.53, 95% CI 0.31 to 0.88, number needed to treat 60) and all types of stroke (OR 0.58, 95% CI 0.35 to 0.94, p=0.038), but also with increased risk of major bleeds (OR 1.9, 95% CI 1.2 to 2.8, number needed to harm 300). In conclusion, after an acute coronary syndrome, A+W and A+C are comparable in the prevention of MAEs, death, and AMI compared with aspirin alone. Allocating 100 patients to A+W (at international normalized ratio 2 to 3) with respect to A+C could prevent 17 thromboembolic strokes while causing 3 major bleeds.
Authors:
Luca Testa; Giuseppe Biondi Zoccai; Italo Porto; Graziana Trotta; Pierfrancesco Agostoni; Felicita Andreotti; Filippo Crea
Related Documents :
9296466 - Low-molecular-weight heparin (fragmin) during instability in coronary artery disease (f...
16118546 - The effects of bivalirudin compared with those of unfractionated heparin plus eptifibat...
22693266 - Occupational exposure to particles and incidence of acute myocardial infarction and oth...
10385786 - Glycoprotein iib/iiia blockade and thrombolytics: early lessons from the speed and gust...
23737896 - Mechanically assisted intra-arterial thrombolysis in acute cerebral infarction.
18062936 - Assessment of heart failure and left ventricular systolic dysfunction after cardiac pac...
Publication Detail:
Type:  Comparative Study; Journal Article; Meta-Analysis     Date:  2007-04-27
Journal Detail:
Title:  The American journal of cardiology     Volume:  99     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-06-11     Completed Date:  2007-09-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1637-42     Citation Subset:  AIM; IM    
Affiliation:
Institute of Cardiology, John Radcliffe Hospital, Oxford, United Kingdom, and Division of Cardiology, University of Turin, Italy. luctes@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / adverse effects,  therapeutic use*
Aspirin / adverse effects,  therapeutic use*
Coronary Disease / drug therapy*
Drug Therapy, Combination
Humans
International Normalized Ratio
Platelet Aggregation Inhibitors / adverse effects,  therapeutic use*
Randomized Controlled Trials as Topic
Risk Assessment
Syndrome
Ticlopidine / adverse effects,  analogs & derivatives*,  therapeutic use
Warfarin / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; 81-81-2/Warfarin; 90055-48-4/clopidogrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effects of aging and physical activity on Doppler measures of diastolic function.
Next Document:  Prevalence and prognosis of asymptomatic left ventricular diastolic dysfunction in ambulatory patien...